The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This stock page is the Follow view. The Build view lets your agent query VTVT owners, fund changes, insider filings, and source links through REST or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/VTVT"
Use Arkolith to show who owns VTVT, which funds added or reduced it, and which SEC filings prove each claim.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | $10.3M | 260K | ▼−3.1% Reduced · −8K sh | Q1 2026 | |
| 2 | MILLENNIUM MANAGEMENT LLC | $8.2M | 206K | ▲New +206K sh | Q1 2026 | |
| 3 | Siren, L.L.C. | $6.5M | 163K | —Held | Q1 2026 | |
| 4 | BAKER BROS. ADVISORS LP | $5.9M | 148K | —Held | Q1 2026 | |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | $4.3M | 109K | ▲New +109K sh | Q1 2026 | |
| 6 | VANGUARD GROUP INC | $3.3M | 83K | ▲+77% Added · +36K sh | Q4 2025 | |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | $1.3M | 33K | ▲+17% Added · +5K sh | Q1 2026 | |
| 8 | NORTHERN TRUST CORP | $716K | 18K | ▲+12% Added · +2K sh | Q1 2026 | |
| 9 | VANGUARD FIDUCIARY TRUST CO | $640K | 16K | ▲New +16K sh | Q1 2026 | |
| 10 | 683 Capital Management, LLC | $635K | 16K | ▼−12% Reduced · −2K sh | Q1 2026 | |
| 11 | MARSHALL WACE, LLP | $531K | 13K | ▲New +13K sh | Q1 2026 | |
| 12 | GOLDMAN SACHS GROUP INC | $529K | 13K | ▲+141% Added · +8K sh | Q1 2026 | |
| 13 | BlackRock, Inc. | $500K | 13K | ▲+19% Added · +2K sh | Q1 2026 | |
| 14 | STATE STREET CORP | $423K | 11K | ▲New +11K sh | Q1 2026 | |
| 15 | Pathstone Holdings, LLC | $241K | 6K | —Held | Q1 2026 | |
| 16 | UBS Group AG | $224K | 6K | ▲+238% Added · +4K sh | Q1 2026 | |
| 17 | Qube Research & Technologies Ltd | $223K | 6K | ▲New +6K sh | Q1 2026 | |
| 18 | MORGAN STANLEY | $46K | 1K | ▲+18% Added · +178 sh | Q1 2026 | |
| 19 | OSAIC HOLDINGS, INC. | $44K | 1K | ▼−0.1% Reduced · −1 sh | Q1 2026 | |
| 20 | Farther Finance Advisors, LLC | $11K | 283 | ▲+1.4% Added · +4 sh | Q1 2026 | |
| 21 | ROYAL BANK OF CANADA | $2K | 43 | ▲New +43 sh | Q1 2026 | |
| 22 | CoreCap Advisors, LLC | $2K | 45 | —Held | Q1 2026 | |
| 23 | Parallel Advisors, LLC | $2K | 38 | —Held | Q1 2026 | |
| 24 | BARCLAYS PLC | $1K | 36 | ▲New +36 sh | Q1 2026 | |
| 25 | BNP PARIBAS FINANCIAL MARKETS | $357 | 9 | —Held | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Feb 17, 2026 | SEKHRI PAUL J | Pres, CEO and Exec Chairperson, Director | Grant (A) | 140K | $5.2M |
| Feb 17, 2026 | Tung Michael Stephen | EVP & CFO | Grant (A) | 45K | $1.7M |
| Sep 22, 2025 | AKKARAJU SRINIVAS | Director | Grant (A) | 106K | $1.6M |
| Sep 22, 2025 | AKKARAJU SRINIVAS | Director | Grant (A) | 877K | — |
| Sep 22, 2025 | AKKARAJU SRINIVAS | Director | Grant (A) | 983K | — |
| Sep 3, 2025 | BAKER JULIAN | Director | Grant (A) | 217K | — |
| Sep 3, 2025 | AKKARAJU SRINIVAS | Director | Grant (A) | 656K | — |
| Sep 3, 2025 | AKKARAJU SRINIVAS | Director | Grant (A) | 656K | — |
| Sep 3, 2025 | BAKER JULIAN | Director | Grant (A) | 4K | — |
| Sep 3, 2025 | BAKER JULIAN | Director | Grant (A) | 2.4M | — |
| Sep 3, 2025 | BAKER JULIAN | Director | Grant (A) | 221K | — |
| Sep 3, 2025 | BAKER JULIAN | Director | Grant (A) | 2.4M | — |
| Company | Co-held by | Combined value |
|---|---|---|
| BEONE MEDICINES LTD-ADRONC | 4 funds | $2.8B |
| REVOLUTION MEDICINES INCRVMD | 4 funds | $1.0B |
| AMAZON.COM INCAMZN | 4 funds | $406.4M |
| ALPHABET INC-CL AGOOGL | 4 funds | $379.3M |
| ARROWHEAD PHARMACEUTICALS INARWR | 4 funds | $227.3M |
| CRINETICS PHARMACEUTICALS INCRNX | 4 funds | $155.4M |
| DENALI THERAPEUTICS INCDNLI | 4 funds | $99.6M |
| WAVE LIFE SCIENCES LTDWVE | 4 funds | $59.3M |
| CYTOMX THERAPEUTICS INCCTMX | 4 funds | $41.6M |
| SAGIMET BIOSCIENCES INC-ASGMT | 4 funds | $5.6M |
| ULTRAGENYX PHARMACEUTICAL INRARE | 4 funds | $780K |
| INCYTE CORPINCY | 3 funds | $2.9B |
Ranked by how many of VTVT's institutional holders also hold each name, a cross-fund conviction signal. Via the MCP server (ticker.co_held).
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for VTVT. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes. Every panel above is one call to the Arkolith API & MCP server.